Inspiring Encounters in the Treatment of Myasthenia Gravis
Kelly G. Gwathmey, MD, Associate Professor, Neuromuscular Division Chief, Department of Neurology, Virginia Commonwealth University, Richmond, Virginia
Kelly G. Gwathmey, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: UCB; Argenx; Alexion; Myasthenia Gravis Foundation of America
Serve(d) as a speaker or a member of a speakers bureau for: Alexion
Kelly G. Gwathmey, MD, recounts shadowing a neurologist during an early phase of academic training and how witnessing examinations of patients with conditions like myasthenia gravis and amyotrophic lateral sclerosis inspired a career path in neuromuscular medicine.
Dr Gwathmey also reflects on the evolution of myasthenia gravis treatment over the past two decades, noting the introduction of new medications like eculizumab, complement inhibitors, and FcRn inhibitors — offering more targeted options and hope for patients with fewer side effects — and anticipates further advancements in treatment leading to improved disease control.
,false